Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB\u2019s Zilucoplan Shows no Relevant Effect in Immune-Mediated Necrotizing Myopathy (IMNM)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Peptide","graph2":"UCB Pharma S.A"},{"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation for GLPG1690 in systemic sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Galapagos"},{"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primary Endpoint Achieved with Ziritaxestat in Novesa Trial in Systemic Sclerosis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Galapagos"}]

UCB Pharma S.A

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

UCB’s Zilucoplan Shows no Relevant Effect in Immune-Mediated Necrotizing Myopathy (IMNM)

Details:

The phase 2 study with zilucoplan, a peptide inhibitor of complement component 5 (C5), in immune-mediated necrotizing myopathy (IMNM) did not show a meaningful effect of zilucoplan for people living with IMNM.

Lead Product(s): Zilucoplan

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2021

ASK
US

Upload
your Pipeline Activity

Galapagos

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Primary Endpoint Achieved with Ziritaxestat in Novesa Trial in Systemic Sclerosis Patients

Details:

Ziritaxestat reached the primary endpoint of the study with a statistically significant change from baseline in the modified Rodnan Skin Score (mRSS) at Week 24, of -8.3 vs -5.7 for placebo.

Lead Product(s): Ziritaxestat

Therapeutic Area: Immunology Product Name: GLPG1690

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 11, 2020

ASK
US

Upload
your Pipeline Activity

Galapagos

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Orphan Drug Designation for GLPG1690 in systemic sclerosis

Details:

With the NOVESA Phase 2 trial in SSc fully recruited, the company expects to see topline data in the second half of the year.

Lead Product(s): Ziritaxestat

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY